Fenbendazole Market Size, Growth Insights and Key Players Shaanxi Hanjiang Pharmaceutical Group Co., Ltd., Hubei KangBaoTai Fine Chemical Co., Ltd, Merck Sharp & Dohme Corp.

Fenbendazole is a broad spectrum anthelmintic drug of class benzimidazole. Fenbendazole is used to remove certain gastrointestinal parasites from the stomach and intestines of animals. It is effective against roundworms, hookworms, whipworms, certain tapeworms, and parasites called strongyles and strongyloides, respectively. Fenbendazole acts as an effective de-wormer as it controls & destroys these worms by preventing their growth and reproduction.

Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2244

Fenbendazole Market Driver

Increasing research and development activities for enhancing the efficiency of fenbendazole in treating various diseases in animals and humans is a major factor boosting growth of the fenbendazole market. For instance, in August 2018, researchers from National Centre for Human Genome Studies and Research (NCHGSR), India, reported that fenbendazole has potential to act as an effective anti-cancer agent. Fenbendazole can also be effective remedy in evading drug resistance commonly encountered in cancer therapy. To study this, researchers first treated human non-small cell lung cancer cells with fenbendazole and found tumor cell death.

Since, developing a promising molecule into an approved drug often consume considerable time and cost, repurposing of veterinary drugs in treating diseases in humans can be effective and have shown promising results and is expected to show cost reduction without need to develop new drugs.

Fenbendazole Market Restraint

Fenbendazole drug resistance due improper or excessive usage of drugs in horses is likely to affect the growth of fenbendazole market. For instance, according to National Equine Health Survey (NEHS) 2016, increasing use of fenbendazole drugs in horses in the U.S. has caused widespread resistance for the drug in these animals. According to the same source, use of fenbendazole drugs in horses for treatment of encysted small red worm causes gut infection in the animals.

Fenbendazole Market – Regional Analysis

On the basis of region, the global fenbendazole market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to hold dominant position in the global fenbendazole market, owing to new developments in pet care and animal health. For instance, in June 2018, Cargill Animal Nutrition, a U.S.-based firm launched NutreBeef Safe-Guard (fenbendazole) Dewormer Mineral (Medicated) in one easy-to-use package. NutreBeef Safe-Guard Dewormer Mineral combines Safe-Guard from Merck Animal Health, with a high quality, free-choice mineral formula from Cargill Animal Nutrition. Safe-Guard goes directly into the gastrointestinal tract of the parasite and once ingested by the parasite, it cannot be excreted thus, accumulation of Safe-Guard in the parasite eventually leads to parasite death.

Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2244

Key players operating in the global fenbendazole market include, Shaanxi Hanjiang Pharmaceutical Group Co., Ltd., Hubei KangBaoTai Fine Chemical Co., Ltd, Merck Sharp & Dohme Corp., Henan Purui Pharmaceutical Co., Ltd., Leo Bio-care Private Limited, Supharma Chem., Intervet Inc., LASA Supergenerics Limited, and Jiangsu Quality Horizons Pharmtech Co., Ltd.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.